IXICO has published a trading update for the 12-months to September 2023 alongside an update on the company’s outlook for FY24. For FY23, IXICO now expects EBITDA to improve on the previous target of a c£1.0m loss despite a small shortfall in revenues following delays in the initiation of clinical trials. With a tight funding environment affecting the biopharmaceutical industry, the company has effectively managed challenges resulting from a contraction in the number of new clinical trial initia ....
